Open AccessImmune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
Author(s) -
Richard S. Hotchkiss,
Elizabeth Colston,
Sachin Yende,
Elliott D. Crouser,
Greg S. Martin,
Timothy E. Albertson,
Raquel R. Bartz,
Scott C. Brakenridge,
Matthew J. Delano,
Pauline K. Park,
Michael W. Donnino,
Mark Tidswell,
Florian Mayr,
Derek C. Angus,
Craig M. Coopersmith,
Lyle L. Moldawer,
Ian M. Catlett,
Ihab Girgis,
June Ye,
Dennis M. Grasela
Publication year - 2019
Publication title -
intensive care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.658
H-Index - 197
eISSN - 1432-1238
pISSN - 0342-4642
DOI - 10.1007/s00134-019-05704-z
Subject(s) - medicine , nivolumab , tolerability , pharmacokinetics , pharmacodynamics , sepsis , cytokine release syndrome , population , gastroenterology , pharmacology , adverse effect , immune system , immunology , immunotherapy , chimeric antigen receptor , environmental health
Sepsis-associated immunosuppression increases hospital-acquired infection and viral reactivation risk. A key underlying mechanism is programmed cell death protein-1 (PD-1)-mediated T-cell function impairment. This is one of the first clinical safety and pharmacokinetics (PK) assessments of the anti-PD-1 antibody nivolumab and its effect on immune biomarkers in sepsis.